Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders

• US 8,394,832 B2
• Filed: 11/30/2005
• Issued: 03/12/2013
• Est. Priority Date: 12/01/2004
• Status: Expired due to Fees

• Current Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Original Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Inventors: Xu, Weiming, Corral, Laura G.
• Primary Examiner(s): THOMAS, TIMOTHY P
• Application Number:
  US11/289,723
• Publication Number:
  US 20060188475A1
• Time in Patent Office: 2,659 Days
• Field of Search: 514/323
• US Class Current: 514/323
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

Claims

1. A method of treating or managing an immunodeficiency disease or disorder, which comprises administering to a patient in need of such treatment or management a therapeutically effective amount of an immunomodulatory compound of formula (I),

2. The method of claim 1, wherein the immunodeficiency disease or disorder is primary immunodeficiency or secondary immunodeficiency.

3. The method of claim 2, wherein the immunodeficiency disease or disorder is primary immunodeficiency.

4. The method of claim 1, wherein the immunodeficiency disease or disorder is X-linked agammaglobulinemia.

5. The method of claim 1, wherein the immunomodulatory compound is 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.

6. The method of claim 5, wherein the immunomodulatory compound is enantiomerically pure.

7. The method of claim 1, wherein the immunomodulatory compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.

8. The method of claim 7, wherein the immunomodulatory compound is enantiomerically pure.

9. The method of claim 1, further comprising administering an anti-CD40 antibody to said patient.

10. The method of claim 1, further comprising administering CD40L to said patient.